{
    "clinical_study": {
        "@rank": "151570", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and\n      effective in lowering viral load (level of HIV in the blood) and raising the level of CD4\n      cells (cells of the body that help fight infection)."
        }, 
        "brief_title": "A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive one of three doses of 1592U89. During this randomized\n      dosing phase, if a patient meets one of the following criteria, he/she is offered open-label\n      1592U89 (300 mg) plus zidovudine (ZDV) plus lamivudine (3TC) (or other licensed\n      antiretrovirals according to standard practice). Criteria are based on falling CD4 counts\n      (return to baseline on two occasions at least 1 month apart), disease progression (defined\n      as occurrence of a new AIDS-defining event according to CDC classification excluding CD4\n      counts less than 200  cells/mm3), or lack of virus suppression (defined as less than\n      0.7log10 reduction in viral load at Week 4 with a repeat value 1 week later, more than 5000\n      copies/ml HIV RNA at Weeks 12, 16, 20, or 24, or 5000 copies/ml or more anytime after Week\n      24)."
        }, 
        "eligibility": {
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002390", 
            "org_study_id": "238H", 
            "secondary_id": "CNAB2002"
        }, 
        "intervention": {
            "intervention_name": "Abacavir sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Abacavir"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 13", 
                        "country": "France"
                    }, 
                    "name": "Group Hospier Pitie-Salpetriere / Maladies Infec et Trop"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 18", 
                        "country": "France"
                    }, 
                    "name": "Groupe Hospitalier Bichat-Claude Bernard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex", 
                        "country": "France"
                    }, 
                    "name": "Hopital de Purpan / CHU de Rangueil / Medecine Interue"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex", 
                        "country": "France"
                    }, 
                    "name": "Hopital de Purpan / Service du Professeur Auvergnat"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany"
                    }, 
                    "name": "Universitat Erlangen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Universitatsklinikurn Frankfurt"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany"
            ]
        }, 
        "official_title": "A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "9833847", 
            "citation": "Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS. 1998 Nov 12;12(16):F197-202."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002390"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {
        "Group Hospier Pitie-Salpetriere / Maladies Infec et Trop": "48.857 2.352", 
        "Groupe Hospitalier Bichat-Claude Bernard": "48.857 2.352", 
        "Hopital de Purpan / CHU de Rangueil / Medecine Interue": "43.605 1.444", 
        "Hopital de Purpan / Service du Professeur Auvergnat": "43.605 1.444", 
        "Universitat Erlangen": "49.591 11.014", 
        "Universitatsklinikurn Frankfurt": "50.111 8.682"
    }
}